1 Journal Club Alcohol, Other Drugs, and Health: Current Evidence January–February 2012.

Slides:



Advertisements
Similar presentations
Journal Club Alcohol, Other Drugs, and Health: Current Evidence November–December 2014.
Advertisements

Journal Club Alcohol, Other Drugs, and Health: Current Evidence May–June 2010.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence July–August 2013.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence March–April 2014.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence May–June 2013.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence July-August 2007.
Journal Club Alcohol and Health: Current Evidence March-April 2007.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence September–October 2008.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence January–February 2009.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence March–April 2009.
Journal Club Alcohol and Health: Current Evidence November–December 2004.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence November-December 2007.
Journal Club Alcohol and Health: Current Evidence May–June 2005.
Journal Club Alcohol and Health: Current Evidence March-April 2005.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence May-June 2007.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence July–August 2009.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence April 2008.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence September–October 2011.
1 Journal Club Alcohol, Other Drugs, and Health: Current Evidence September–October 2010.
Journal Club Alcohol and Health: Current Evidence July-August 2006.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence July–August 2008.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence September–October 2009.
1 Journal Club Alcohol, Other Drugs, and Health: Current Evidence July–August 2011.
1 Journal Club Alcohol, Other Drugs, and Health: Current Evidence May–June 2011.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence September-October 2007.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence March–April 2010.
Journal Club Alcohol and Health: Current Evidence May-June 2006.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence January–February 2011.
Journal Club Alcohol and Health: Current Evidence July–August 2004.
Journal Club Alcohol and Health: Current Evidence September–October 2004.
Journal Club Alcohol and Health: Current Evidence January-February 2005.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence May–June 2009.
Journal Club Alcohol and Health: Current Evidence September-October 2005.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence July–August 2014.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence March–April 2015.
Journal Club Alcohol and Health: Current Evidence January–February 2007.
1 Journal Club Alcohol, Other Drugs, and Health: Current Evidence November–December 2010.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence January–February 2010.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence November–December 2008.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence May-June 2008.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence November–December 2009.
1 Journal Club Alcohol, Other Drugs, and Health: Current Evidence July–August 2012.
1 Journal Club Alcohol, Other Drugs, and Health: Current Evidence January–February 2014.
Journal Club Sidharth Bagga MD. Cytisus laborium L. (Golden rain acacia)
Journal Club Alcohol, Other Drugs, and Health: Current Evidence May–June 2012.
1 Journal Club Alcohol, Other Drugs, and Health: Current Evidence March–April 2012.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence May–June 2014.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence September–October 2012.
Focus Area 24 Respiratory Diseases Progress Review June 29, 2004.
1 Journal Club Alcohol, Other Drugs, and Health: Current Evidence September–October 2015.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence November-December 2012.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence November-December, 2015.
G. Biondi Zoccai – Ricerca in cardiologia What to expect? Core modules IntroductionIntroduction Finding out relevant literatureFinding out relevant literature.
Daniel B. Jamieson, Elizabeth C. Matsui, Andrew Belli1, Meredith C. McCormack, Eric Peng Simon Pierre-Louis, Jean Curtin-Brosnan, Patrick N. Breysse, Gregory.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence September–October 2013.
Critical Appraisal II Prepared by Dr. Hoda Abd El Azim.
Alcohol, Other Drugs, and Health: Current Evidence July–August 2017
Alcohol, Other Drugs, and Health: Current Evidence
Alcohol, Other Drugs, and Health: Current Evidence
Alcohol, Other Drugs, and Health: Current Evidence March–April 2017
Alcohol, Other Drugs, and Health: Current Evidence May-June, 2018
Alcohol, Other Drugs, and Health: Current Evidence March–April 2018
Alcohol, Other Drugs, and Health: Current Evidence
Modelled mean (SEM) observed forced vital capacity (FVC) volume change from baseline (mL) over time by dose intensity (>90%, ≤90%), based on actual dose.
Did not have a usual source of care Went without care because of cost
Section II: Lipid management
Alcohol, Other Drugs, and Health: Current Evidence July-August, 2018
Types of questions TVEM can answer
Alcohol, Other Drugs, and Health: Current Evidence
Alcohol, Other Drugs, and Health: Current Evidence May–June 2019
Presentation transcript:

1 Journal Club Alcohol, Other Drugs, and Health: Current Evidence January–February 2012

2 Featured Article Association between Marijuana Exposure and Pulmonary Function Over 20 Years Pletcher MJ, et al. JAMA. 2012;307(2):173–181.

3 Study Objective To analyze the association between current and lifetime marijuana use and pulmonary function.

4 Study Design Longitudinal study * that assessed pulmonary function and smoking from 1985–2006 in a cohort of 5115 men and women from 4 US cities. Participants underwent baseline examination and 6 follow-up examinations. Pulmonary function testing was performed at baseline and years 2, 5, 10, and 20. Lifetime exposure to marijuana was expressed in joint-years, with 1 joint-year of exposure equivalent to smoking 365 joints or filled pipe bowls. *Coronary Artery Risk Development in Young Adults (CARDIA) study.

5 Assessing Validity of an Article About Harm Are the results valid? What are the results? How can I apply the results to patient care?

6 Are the Results Valid? Did the investigators demonstrate similarity in all known determinants of outcomes? Did they adjust for differences in the analysis? Were exposed patients equally likely to be identified in the two groups? Were the outcomes measured in the same way in the groups being compared? Was follow-up sufficiently complete?

7 Did the investigators demonstrate similarity in all known determinants of outcomes? Did they adjust for differences in the analysis? Mixed linear modeling was used to account for individual age-based trajectories of pulmonary function and other covariables *, including tobacco use, which was analyzed in parallel as a positive control. Approximately equal numbers of self-identified “black, not Hispanic” and “white, not Hispanic” men and women were recruited to ensure an adequate sample of the largest minority group in the US at baseline (1985). *Race, sex, age, height, waist circumference, secondhand smoke exposure, exposure to airborne particulates (using study-city yearly averages), education level, and asthma.

8 Were exposed patients equally likely to be identified in the groups?  Yes. −The sample included only participants (n=5016) whose visits provided complete data on pulmonary function, smoking behavior (tobacco and marijuana), secondhand smoke exposure, height, and waist circumference.

9 Were the outcomes measured in the same way in the groups being compared?  Yes. −Forced expiratory volume in the first second of expiration (FEV 1 ) and force vital capacity (FVC) were measured in the same way for all participants.

10 Was follow-up sufficiently complete? Participants contributed an average of 3.9 pulmonary-function measurements per person over the course of 20 years. Fifty-six percent of the sample (2807 participants) attended the year-20 examination.

11 What are the Results? How strong is the association between exposure and outcomes? How precise is the estimate of the risk?

How strong is the association between exposure and outcome? How precise is the estimate of the risk? In adjusted models that considered 4-level categorizations of current and lifetime exposure, compared with zero exposure, –FVC increased with greater lifetime exposure in joint-years (p=0.01), and FEV 1 increased with greater lifetime exposure of up to 10 joint-years and then declined to 36 mL (95% CI, −6.5 to 79) greater than the zero exposure level (p=0.049). –FVC increased with smoking intensity up to 20 marijuana smoking episodes in the past 30 days and then declined to 20 mL greater than the zero exposure level (p=0.03).

13 How Can I Apply the Results to Patient Care? Were the study patients similar to the patients in my practice? Was the duration of follow-up adequate? What was the magnitude of the risk? Should I attempt to stop the exposure?

14 Were the study patients similar to the patients in my practice? The sample was comprised of black and white women and men from 4 large US cities who were aged 18–30 years and healthy at enrollment in 1985.

15 Was the duration of follow-up adequate? The follow-up period was 20 years.

16 What was the magnitude of the risk? Low level marijuana exposure was not associated with declines in pulmonary function. The study was not able to confirm whether heavy marijuana exposure was associated with impairments in pulmonary function.

17 Should I attempt to stop the exposure? From a pulmonary standpoint, there appears to be no adverse impact from low- level marijuana exposure.